Hepatic Arterial Infusion (HAI) of Abraxane

Completed · Phase 1

Conditions studied: Liver Cancer, Advanced Cancers, Solid Tumors

In brief

The goal of this clinical research study is find the highest tolerated dose of Abraxane (nab-paclitaxel) that can be given directly into the liver of patients with advanced cancer that has spread to the liver.

Key facts

Study ID

NCT00732836

Run by

M.D. Anderson Cancer Center

People needed

64

Starts

2008-06-01

Expected to finish

2016-01-01

Last updated by the study team

2016-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically confirmed diagnosis of advanced malignancy and liver involvement as predominant site of metastasis.
• An Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Adequate end-organ function as follows: Absolute neutrophil count (ANC) > or = 1500/mm3, Platelets > or = 100,000/mm3, Creatinine < or = 2.0 mg/dL or the calculated Glomerular filtration rate (GFR) > or = 40 mL/min if Creatinine > 2.0 mg/dL, ALT < or = 5 times upper limits of normal, Hb > 9.0 and Bilirubin < or = 2.0 mg/dL.
• Refractory to standard cancer therapy or who have no conventional therapy that produces a complete response rate of at least 10% or an increase in survival of at least 3 months.
• Ability to fully comprehend and willingness to sign the Institutional Review Board (IRB) approved informed consent
• Full recovery from any previous therapy and ability to receive cytotoxic agents.
• Patient is 18 years of age or older

You may not qualify if…

• Clinically significant ascites.
• Pregnant or breastfeeding females. Women of childbearing potential should be advised to avoid becoming pregnant and men to not father a child while receiving treatment. Women of childbearing potential must have a negative pregnancy test.
• Hypersensitivity to Abraxane
• Untreatable bleeding diathesis
• Evidence of portal vein thrombosis and clinically significant peripheral vascular disease
• Neuropathy of grade 2 or higher
• A known history of central nervous system (CNS) metastasis unless the patients are neurologically stable after treatment with surgery and/or radiation therapy
• If the patient progressed on abraxane previously they will not be eligible for the dose escalation portion or the PK studies only. These patients can be included in the dose expansion portion of the trial.

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.